Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2021 | CheckMate 274 & EV-301: highlights in UC from ASCO GU

Srikala Sridhar, MD, FRCPC, Princess Margaret Cancer Centre, Toronto, ON, provides a summary of her key highlights from ASCO GU 2021 in the field of urothelial carcinoma (UC). Dr Sridhar described the initial results from the Phase III CheckMate 274 trial (NCT02632409), which demonstrated that in patients treated with adjuvant nivolumab following radical surgery for high-risk muscle-invasive UC, a significant improvement in disease-free survival was observed compared to placebo. The Phase III EV-301 study (NCT03474107) also demonstrated that enfortumab vedotin, an antibody-drug conjugate directed to Nectin-4, had a significant survival advantage over chemotherapy in patients with previously treated locally advanced or metastatic UC. This interview took place during the 2021 Genitourinary Cancers Symposium.